Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Stock Price: $52.87

+0.7 (1.34%)

Updated Feb 2, 2023 09:00 PM GMT+0000

Featured app

Invest now

<p>79% of retail CFD accounts lose money</p>

Overview

Financials

Statistics

Profile

Chart

Market Cap	7.15B
Revenue	580.62M
Gross Profit	461.85M
Shares Out	135.21M
EPS (ttm)	1.49
PE Ratio	33.8486
Forward PE	16.9130
Dividend Rate (ttm)	0.0000
Dividend Yield	0.0000

Trading Day	Feb 2
Last Price	$52.87
Previous Close	$52.17
Change ($)	0.7
Change (%)	1.34%
Day's Open	52.17
Day's Range	Market Closed
Day's Volume	1.09M
52 Week Range	32 - 59.46

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success.

Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics.

Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.

News

Pro: ‘S&P 500 in a recession is fairly valued at 2,800 to 3,200’ November 11, 2022

Quick info

Country

United States

Industry

Biological Product (except Diagnostic) Manufacturing

Sector

Manufacturing

Employees

145

CEO

Helen Torley

Address

11388 Sorrento Valley Rd
San Diego
California
92121-1345

Phone

18587948889

Website

www.halozyme.com

Ticker Symbol

HALO

Exchange

NASDAQ Stock Exchange

Reporting Currency

USD

Halozyme Therapeutics, Inc. income statements (2022) (USD)

	August 2022	August 2022	May 2022	February 2022
Total Revenue	152.37M	152.37M	117.28M	102M
Cost of Revenue	33.94M	33.94M	15.92M	21.59M
Gross Profit	118.42M	118.42M	101.36M	80.42M
Research & Development	15.48M	15.48M	11.85M	10.11M
Selling General & Admin	57.48M	57.48M	13.83M	13.77M
Operating Expense	118.31M	118.31M	41.61M	45.47M
Operating Income	34.06M	34.06M	75.67M	56.53M
Other Income Expense Net	0	0	0	0
EBIT	34.06M	34.06M	75.67M	56.53M
Interest Income	3.10M	3.10M	1.76M	2.06M
Pretax Income	30.01M	30.01M	74.41M	54.81M
Income Tax	7.33M	7.33M	14.30M	-11.96M
Minority Interest	0	0	0	0
Net Income	22.69M	22.69M	60.11M	66.77M
Net Income Basic	22.69M	22.69M	60.11M	66.77M

Halozyme Therapeutics, Inc. income statements (2021) (USD)

	November 2021	August 2021	May 2021	February 2021
Total Revenue	115.83M	136.46M	89.02M	121.70M
Cost of Revenue	18.59M	23.02M	18.22M	26.27M
Gross Profit	97.24M	113.44M	70.80M	95.43M
Research & Development	8.49M	8.07M	9.01M	7.38M
Selling General & Admin	13.17M	12.32M	11.06M	10.43M
Operating Expense	40.24M	43.41M	38.29M	44.08M
Operating Income	75.59M	93.05M	50.74M	77.62M
Other Income Expense Net	0	0	0	0
EBIT	75.59M	93.05M	50.74M	77.62M
Interest Income	1.75M	1.75M	1.97M	5.04M
Pretax Income	74.11M	91.52M	28.09M	73.25M
Income Tax	-142.48M	58K	191K	85K
Minority Interest	0	0	0	0
Net Income	216.59M	91.46M	27.90M	73.16M
Net Income Basic	216.59M	91.46M	27.90M	73.16M

Halozyme Therapeutics, Inc. income statements (2020) (USD)

	November 2020	June 2020	March 2020	March 2020
Total Revenue	65.32M	55.22M	25.35M	25.35M
Cost of Revenue	5.57M	5.74M	5.79M	5.79M
Gross Profit	59.75M	49.48M	19.57M	19.57M
Research & Development	7.75M	8.95M	10.16M	10.16M
Selling General & Admin	11.70M	10.98M	12.63M	12.63M
Operating Expense	25.02M	25.67M	28.58M	28.58M
Operating Income	40.30M	29.56M	-3.22M	-3.22M
Other Income Expense Net	0	-3.68M	-2.87M	-2.87M
EBIT	40.30M	29.56M	-3.22M	-3.22M
Interest Income	4.99M	5M	5.35M	5.35M
Pretax Income	36.27M	25.88M	-6.09M	-6.09M
Income Tax	63K	58K	11K	11K
Minority Interest	0	0	0	0
Net Income	36.21M	25.82M	-6.1M	-6.1M
Net Income Basic	36.21M	25.82M	-6.1M	-6.1M

Halozyme Therapeutics, Inc. income statements (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Total Revenue	53.67M	46.23M	39.15M	56.95M
Cost of Revenue	16.69M	22.33M	2.88M	4.65M
Gross Profit	36.98M	23.90M	36.27M	52.30M
Research & Development	27.91M	30.46M	32.91M	31.33M
Selling General & Admin	10.17M	17.98M	17.34M	18.01M
Operating Expense	54.77M	70.77M	53.13M	53.98M
Operating Income	-1.1M	-24.54M	-13.98M	2.97M
Other Income Expense Net	-33.36M	-465K	-630K	-1.15M
EBIT	-1.1M	-24.54M	-13.98M	2.97M
Interest Income	3.73M	2.08M	2.61M	3.21M
Pretax Income	-34.46M	-25M	-14.61M	1.82M
Income Tax	-63K	13K	17K	22K
Minority Interest	0	0	0	0
Net Income	-34.4M	-25.02M	-14.62M	1.80M
Net Income Basic	-34.4M	-25.02M	-14.62M	1.80M

Halozyme Therapeutics, Inc. income statements (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Total Revenue	60.23M	25.56M	35.20M	30.87M
Cost of Revenue	5.62M	626K	836K	3.05M
Gross Profit	54.61M	24.93M	34.37M	27.82M
Research & Development	36.65M	35.54M	40.09M	37.98M
Selling General & Admin	18.03M	14.86M	14.35M	13.56M
Operating Expense	60.30M	51.03M	55.28M	54.58M
Operating Income	-71K	-25.47M	-20.07M	-23.71M
Other Income Expense Net	-1.74M	-2.38M	-2.79M	-3.56M
EBIT	-71K	-25.47M	-20.07M	-23.71M
Interest Income	3.76M	4.29M	4.77M	5.23M
Pretax Income	-1.81M	-27.85M	-22.86M	-27.27M
Income Tax	317K	N.A	33K	187K
Minority Interest	0	0	0	0
Net Income	-2.13M	-27.85M	-22.89M	-27.46M
Net Income Basic	-2.13M	-27.85M	-22.89M	-27.46M

Halozyme Therapeutics, Inc. income statements (2017) (USD)

	December 2017	September 2017	June 2017
Total Revenue	189.56M	63.73M	33.75M
Cost of Revenue	7.49M	8.33M	7.79M
Gross Profit	182.08M	55.40M	25.96M
Research & Development	41.38M	33.99M	38.34M
Selling General & Admin	14.77M	13.33M	13.10M
Operating Expense	63.64M	55.65M	59.23M
Operating Income	125.93M	8.08M	-25.48M
Other Income Expense Net	-4.38M	-4.75M	-5.11M
EBIT	125.93M	8.08M	-25.48M
Interest Income	5.46M	5.54M	5.54M
Pretax Income	121.55M	3.33M	-30.58M
Income Tax	-2.33M	580K	180K
Minority Interest	0	0	0
Net Income	123.88M	2.75M	-30.76M
Net Income Basic	123.88M	2.75M	-30.76M

Halozyme Therapeutics, Inc. balance sheet (2022) (USD)

	August 2022
Current Cash	209.36M
Receivables	189.37M
Inventory	97.62M
Current Assets	541.94M
Other Current Assets	45.60M
Short Term Investments	45.60M
Long Term Investments	1.24B
Property/Plant Equipment	31.37M
Good Will	N.A
Intangible Assets	0.98B
Tangible Assets (Net)	-882.41M
Other Assets	26.28M
Total Assets	1.78B
Accounts Payable	12.23M
Other Current Liabilities	88.23M
Total Current Liabilities	199.51M
Total Liabilities	1.49B
Long Term Debt	1.15B
Current Long Term Debt	99.05M
Minority Interest	0
Common Stock	137.94M
Treasury Stock	0
Retained Earnings	23.88M
Capital Surplus	N.A
Shareholder Equity	293.17M
Other Liabilities	N.A

Halozyme Therapeutics, Inc. balance sheet (2020) (USD)

	November 2020	June 2020	March 2020	March 2020
Current Cash	346.71M	133.61M	104.82M	104.82M
Receivables	62.55M	37.40M	29.75M	29.75M
Inventory	57.70M	48.27M	41.45M	41.45M
Current Assets	498.90M	500.36M	467.97M	467.97M
Other Current Assets	31.94M	29.24M	28.59M	28.59M
Short Term Investments	31.94M	251.84M	263.36M	263.36M
Long Term Investments	25.13M	500K	500K	500K
Property/Plant Equipment	10.25M	11.17M	11.75M	11.75M
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	0	N.A	N.A	N.A
Tangible Assets (Net)	98.99M	105.58M	58.04M	58.04M
Other Assets	14.38M	14.97M	12.13M	12.13M
Total Assets	524.03M	527M	492.35M	492.35M
Accounts Payable	433K	4.07M	8.32M	8.32M
Other Current Liabilities	26.54M	20.33M	30.82M	30.82M
Total Current Liabilities	26.98M	26.07M	42M	42M
Total Liabilities	425.04M	421.42M	434.31M	434.31M
Long Term Debt	393.63M	390.08M	386.57M	386.57M
Current Long Term Debt	0	N.A	2.86M	2.86M
Minority Interest	0	0	0	0
Common Stock	646.32M	136.67M	135.36M	135.36M
Treasury Stock	0	N.A	N.A	N.A
Retained Earnings	-547.76M	-583.96M	-609.78M	-609.78M
Capital Surplus	N.A	688.32M	667.68M	667.68M
Shareholder Equity	98.99M	105.58M	58.04M	58.04M
Other Liabilities	N.A	N.A	N.A	N.A

Halozyme Therapeutics, Inc. balance sheet (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Current Cash	120.18M	59.20M	67.04M	60.60M
Receivables	59.44M	40.74M	32.22M	28.16M
Inventory	29.36M	36.05M	43.90M	31.24M
Current Assets	543.44M	342.04M	391.71M	409.04M
Other Current Assets	33.37M	27.25M	28.12M	20.91M
Short Term Investments	301.08M	178.80M	220.42M	268.12M
Long Term Investments	500K	500K	500K	500K
Property/Plant Equipment	10.86M	15.40M	15.08M	14.54M
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	N.A	N.A	N.A	N.A
Tangible Assets (Net)	91.77M	245.35M	260.05M	260.05M
Other Assets	11.08M	12.42M	10.55M	5.03M
Total Assets	565.87M	370.36M	417.83M	429.11M
Accounts Payable	6.43M	4.31M	12.47M	4.09M
Other Current Liabilities	59.66M	49.19M	52.07M	47.91M
Total Current Liabilities	85.64M	108.04M	135.42M	138.66M
Total Liabilities	474.11M	125M	157.78M	169.06M
Long Term Debt	383.05M	9.31M	14.08M	18.74M
Current Long Term Debt	19.54M	54.54M	70.88M	86.66M
Minority Interest	0	0	0	0
Common Stock	136.71M	146.46M	145.86M	145.37M
Treasury Stock	N.A	N.A	N.A	N.A
Retained Earnings	-603.68M	-569.28M	-544.27M	-529.64M
Capital Surplus	695.07M	814.10M	803.78M	789.48M
Shareholder Equity	91.77M	245.35M	260.05M	260.05M
Other Liabilities	N.A	N.A	N.A	N.A

Halozyme Therapeutics, Inc. balance sheet (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Current Cash	57.94M	55.02M	55.17M	98.01M
Receivables	30.01M	27.66M	33.58M	26.57M
Inventory	22.63M	18.29M	8.40M	4.39M
Current Assets	427.85M	429.93M	462.03M	484.47M
Other Current Assets	20.69M	19.62M	21.15M	19.81M
Short Term Investments	296.59M	309.35M	343.72M	335.68M
Long Term Investments	500K	500K	500K	500K
Property/Plant Equipment	7.47M	6.79M	4.79M	4.94M
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	N.A	N.A	N.A	N.A
Tangible Assets (Net)	248.89M	239.74M	254.93M	265.06M
Other Assets	4.43M	7.29M	7.43M	5.56M
Total Assets	440.25M	444.51M	474.75M	495.47M
Accounts Payable	4.08M	3.33M	6.19M	3.63M
Other Current Liabilities	53.78M	47.27M	39.28M	33.14M
Total Current Liabilities	149.36M	139.12M	132.43M	119.22M
Total Liabilities	191.36M	204.77M	219.83M	230.41M
Long Term Debt	34.87M	57.94M	79.08M	102.70M
Current Long Term Debt	91.51M	88.52M	86.97M	82.46M
Minority Interest	0	0	0	0
Common Stock	144.73M	144.52M	144.22M	143.89M
Treasury Stock	N.A	N.A	N.A	N.A
Retained Earnings	-531.44M	-529.31M	-501.46M	-478.57M
Capital Surplus	780.46M	769.38M	756.98M	744.36M
Shareholder Equity	248.89M	239.74M	254.93M	265.06M
Other Liabilities	N.A	N.A	N.A	N.A

Halozyme Therapeutics, Inc. balance sheet (2017) (USD)

	December 2017	September 2017	June 2017
Current Cash	168.74M	164.40M	114.75M
Receivables	22.13M	14.70M	14.47M
Inventory	5.15M	9.33M	15.17M
Current Assets	510.37M	353.35M	340.83M
Other Current Assets	13.88M	12.40M	13.66M
Short Term Investments	300.47M	152.53M	182.79M
Long Term Investments	500K	500K	500K
Property/Plant Equipment	3.52M	3.23M	3.33M
Good Will	N.A	N.A	N.A
Intangible Assets	N.A	N.A	N.A
Tangible Assets (Net)	208.37M	72.39M	58.17M
Other Assets	5.55M	72K	122K
Total Assets	519.95M	357.15M	344.79M
Accounts Payable	7.95M	4.15M	5.65M
Other Current Liabilities	46.17M	36.46M	31.45M
Total Current Liabilities	131.33M	102.05M	82.62M
Total Liabilities	311.58M	284.76M	286.62M
Long Term Debt	125.14M	145.42M	165.52M
Current Long Term Debt	77.21M	61.43M	45.52M
Minority Interest	0	0	0
Common Stock	142.79M	142.30M	141.91M
Treasury Stock	N.A	N.A	N.A
Retained Earnings	-522.37M	-646.25M	-649M
Capital Surplus	731.04M	718.55M	707.09M
Shareholder Equity	208.37M	72.39M	58.17M
Other Liabilities	N.A	N.A	N.A

Halozyme Therapeutics, Inc. cash flow (2022) (USD)

	November 2022	August 2022
Net Income	61.63M	22.69M
Depreciation	29.20M	12.55M
Changes in Receivables	233.30M	189.37M
Changes in Inventories	103.28M	97.62M
Cash Change	265.58M	209.36M
Cash Flow	69.64M	40.23M
Capital Expenditures	-1.01M	-0.97M
Investments	N.A	N.A
Investing Activity (other)	N.A	N.A
Total Investing Cash Flows	-1.01M	-434.95M
Dividends Paid	N.A	N.A
Net Borrowings	1.19B	0.99B
Other Financing Cash Flows	N.A	N.A
Cash Flow Financing	-12.4M	367.82M
Exchange Rate Effect	N.A	N.A

Halozyme Therapeutics, Inc. cash flow (2020) (USD)

	November 2020	June 2020	March 2020
Net Income	36.21M	25.82M	-6.1M
Depreciation	2.48M	824K	857K
Changes in Receivables	25.15M	-7.65M	29.69M
Changes in Inventories	9.43M	-6.82M	-12.09M
Cash Change	-38.74M	28.79M	-15.36M
Cash Flow	4.53M	3.29M	-4.84M
Capital Expenditures	-805K	-515K	-114K
Investments	N.A	12.41M	37.49M
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	19.91M	11.90M	38.11M
Dividends Paid	N.A	N.A	N.A
Net Borrowings	14.98M	-2.86M	-16.7M
Other Financing Cash Flows	N.A	68K	-68K
Cash Flow Financing	-78.89M	13.59M	-48.62M
Exchange Rate Effect	N.A	N.A	N.A

Halozyme Therapeutics, Inc. cash flow (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Net Income	-34.4M	-25.02M	-14.62M	1.80M
Depreciation	1.04M	1M	1.03M	0.99M
Changes in Receivables	-18.7M	-8.53M	-4.06M	1.84M
Changes in Inventories	6.69M	7.85M	-12.66M	-8.62M
Cash Change	60.98M	-7.84M	6.45M	2.66M
Cash Flow	-26.63M	-29.59M	-24.79M	-4.42M
Capital Expenditures	-641K	-1.1M	-1.37M	-0.93M
Investments	-122.18M	42.10M	48.83M	29.74M
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-122.82M	41M	47.46M	28.81M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	402.29M	-21.33M	-20.69M	-21.28M
Other Financing Cash Flows	N.A	N.A	N.A	N.A
Cash Flow Financing	210.42M	-19.25M	-16.23M	-21.73M
Exchange Rate Effect	N.A	N.A	N.A	N.A

Halozyme Therapeutics, Inc. cash flow (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Net Income	-2.13M	-27.85M	-22.89M	-27.46M
Depreciation	590K	612K	620K	566K
Changes in Receivables	-2.35M	5.93M	-7.01M	-4.44M
Changes in Inventories	-4.34M	-9.88M	-4.01M	752K
Cash Change	2.92M	-154K	-42.84M	-70.73M
Cash Flow	10.46M	-18.93M	-18.86M	-22.18M
Capital Expenditures	-3.07M	-333K	-418K	-839K
Investments	13.88M	35.52M	-7.19M	-35.06M
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	10.81M	35.19M	-7.61M	-35.9M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	-20.42M	-19.96M	-19.52M	-17.63M
Other Financing Cash Flows	N.A	N.A	N.A	N.A
Cash Flow Financing	-18.35M	-16.42M	-16.37M	-12.65M
Exchange Rate Effect	N.A	N.A	N.A	N.A

Halozyme Therapeutics, Inc. cash flow (2017) (USD)

	December 2017	September 2017	June 2017
Net Income	123.88M	2.75M	-30.76M
Depreciation	493K	496K	570K
Changes in Receivables	-7.44M	-222K	-2.02M
Changes in Inventories	4.19M	5.84M	-882K
Cash Change	4.34M	49.65M	69.56M
Cash Flow	153.25M	20.26M	-17M
Capital Expenditures	-860K	-161K	-230K
Investments	-148.13M	30.44M	-49.06M
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	-148.99M	30.28M	-49.29M
Dividends Paid	N.A	N.A	N.A
Net Borrowings	-5.01M	-4.6M	-3.4M
Other Financing Cash Flows	N.A	N.A	N.A
Cash Flow Financing	82K	-890K	135.85M
Exchange Rate Effect	N.A	N.A	N.A